Navigation Links
PDL BioPharma Completes Regular Quarterly Dividend Payment
Date:6/16/2011

INCLINE VILLAGE, Nev., June 16, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the June 15, 2011, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of June 8, 2011, the record date.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed by leading pharmaceutical and biotechnology companies today based on patents which expire in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
3. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
4. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
9. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... ROCKVILLE, Md. , July 11, 2017  The ... had estimated revenues of approximately $394.1 million in 2016.  ... a trend of solid growth, in particular as a ... oncology clinical practice, and the recent introduction of a ... the need for less-invasive testing of tumor biomarkers to ...
(Date:7/10/2017)... 10, 2017 The Institute for In Vitro ... the recipient of a VITROCELL® inhalation exposure system thanks ... Consortium. The device, which is designed to replace animals ... lung cells to airborne test materials in an environment ... VITROCELL® system for testing combustible tobacco products, as well ...
(Date:7/5/2017)... -- Wolfmet 3D  printed tungsten collimator manufactured by M&I Materials proves ... to progress molecular radiotherapy imaging. In molecular radiotherapy ... accurately quantify the radiation absorbed by those patients undergoing treatment. ... this radiotherapy treatment has been available — that is, until ... ...
Breaking Medicine Technology:
(Date:7/20/2017)... , ... July 20, 2017 , ... Team Type 1 ... to medicine for everyone affected by diabetes, is teaming up with a Microsoft Corp. ... event kicks off on July 24th. , “Team Type 1’s mission overlaps seamlessly ...
(Date:7/20/2017)... ... , ... The Dermatology Clinic announced today the addition of Dr. Scott W. ... LSU, graduating summa cum laude. He attended Emory University School of Medicine in Atlanta ... Dr. Dunbar moved to New York to complete an AGCME-accredited Mohs surgery fellowship to ...
(Date:7/20/2017)... ... July 20, 2017 , ... A budget proposal to switch to an alternate ... - adjustment (COLA) is a bad deal for older and disabled Americans, says ... would grow even more slowly than the conventional one that is currently used to ...
(Date:7/20/2017)... ... July 19, 2017 , ... Med Tech Solutions (MTS), a leading health ... business unit of Constellation Inc., a move that will help the company better serve ... St. Louis, the acquisition is expected to help MTS expand its presence ...
(Date:7/20/2017)... ... 2017 , ... “Fidget”: a fun-filled, action-packed memoir of adventures. “Fidget” is the ... drama teacher who was a summa cum laude graduate of Gardner Webb University. She ... award. After her retirement from public school, Lynn continued to pursue her love for ...
Breaking Medicine News(10 mins):